Our Pricing

Mounjaro Maintenance Dose - Prescription Weight Loss UK

Reaching your goal weight on Mounjaro is a significant achievement, but understanding the right mounjaro maintenance dose uk strategy is crucial for long-term success. At Cured Pharmacy, our UK-registered clinical team provides ongoing prescriber support to help you transition from active weight loss to sustainable weight maintenance with tirzepatide therapy.

Understanding Mounjaro Maintenance Dosing After Goal Weight

Once you've achieved your target weight on Mounjaro (tirzepatide), the question becomes: what dose should you stay on? Unlike the structured escalation phase, maintenance dosing is highly individualised and depends on factors including your response to treatment, side effect profile, and weight stability [1].

Clinical evidence from the SURMOUNT-4 trial demonstrated that patients who discontinued tirzepatide after reaching their goal weight regained an average of 14% body weight over 52 weeks, whilst those who continued treatment maintained their weight loss [1]. This underscores the importance of ongoing therapy rather than complete cessation.

Most UK prescribers recommend continuing on your current effective dose for at least 12 weeks after reaching goal weight to assess stability. If weight remains stable with minimal side effects, some patients may trial a stepwise reduction to the lowest effective maintenance dose, typically between 5mg and 10mg weekly [2].

Choosing Your Mounjaro Maintenance Dose: Clinical Considerations

The optimal maintenance dose varies significantly between individuals. In clinical practice, we observe three common maintenance patterns: patients who maintain best on their maximum titrated dose (typically 10mg or 15mg), those who successfully reduce to a mid-range dose (7.5mg), and a smaller group who achieve stability on the lowest 5mg dose [2].

Your UK prescriber will assess several factors when determining your maintenance strategy: the dose at which you achieved goal weight, your rate of weight loss during treatment, presence of any ongoing appetite regulation needs, tolerability of side effects, and your metabolic health markers including HbA1c if you have type 2 diabetes.

Stepwise Dose Reduction Protocol

If you and your prescriber decide to trial a lower maintenance dose, reduction should occur gradually over 8-12 weeks. A typical protocol involves decreasing by one dose level (e.g., from 15mg to 12.5mg, or 10mg to 7.5mg) and monitoring weight stability for at least 4 weeks before considering further reduction [2].

Weight fluctuations of up to 2kg are normal and don't necessarily indicate treatment failure. However, if you regain more than 5% of your lost weight on a reduced dose, your prescriber may recommend returning to your previous effective dose.

Long-Term Mounjaro Treatment: What the Evidence Shows

The SURMOUNT clinical trial programme has provided robust data on long-term tirzepatide use. In SURMOUNT-1, patients maintained an average 20.9% body weight reduction at 72 weeks on the 15mg dose, with weight plateaus typically occurring between weeks 36-52 [3].

Safety data from extended follow-up studies spanning up to 104 weeks show that the side effect profile of Mounjaro remains consistent over time, with gastrointestinal symptoms (nausea, diarrhoea, constipation) typically diminishing after the first 20 weeks of treatment [3]. This suggests that long-term maintenance therapy is well-tolerated for most patients.

Importantly, metabolic benefits extend beyond weight loss alone. Patients maintaining tirzepatide therapy demonstrated sustained improvements in blood pressure, lipid profiles, and inflammatory markers throughout extended treatment periods [1][3].

Monitoring Requirements During Maintenance

UK prescribing guidelines recommend ongoing clinical review every 12 weeks during the maintenance phase. Your prescriber will assess weight stability, side effect burden, treatment adherence, and whether continued prescription remains clinically appropriate. Regular monitoring ensures that Mounjaro continues to provide benefit without unnecessary risk.

Lifestyle Integration: Beyond Medication Alone

Whilst Mounjaro provides powerful pharmacological support for weight maintenance, sustainable results require integration with lifestyle modifications. The medication works by reducing appetite and slowing gastric emptying, but these effects are most effective when combined with structured eating patterns and regular physical activity [2].

During the maintenance phase, focus shifts from calorie restriction to establishing sustainable eating behaviours. Most patients find that Mounjaro's appetite-suppressing effects allow them to maintain a moderate calorie intake (typically 1,500-2,000 kcal daily for women, 1,800-2,400 kcal for men) without the hunger that typically accompanies weight loss maintenance.

Physical activity becomes increasingly important during maintenance. Whilst Mounjaro helps preserve lean muscle mass better than diet alone, resistance training 2-3 times weekly helps maintain metabolic rate and prevents the adaptive thermogenesis that often leads to weight regain [4].

When to Consider Stopping Mounjaro: Exit Strategies

Some patients may wish to discontinue Mounjaro after achieving stable weight maintenance, though this decision should always involve careful discussion with your UK prescriber. The SURMOUNT-4 trial data suggests that discontinuation carries significant risk of weight regain, but certain patient groups may successfully maintain weight loss after cessation [1].

Candidates who may consider a supervised discontinuation trial include those who have maintained goal weight for over 12 months, have established robust lifestyle habits, demonstrate strong intrinsic motivation, and have addressed underlying behavioural factors that contributed to initial weight gain. Even in these cases, close monitoring during the 6 months post-cessation is essential.

If you do discontinue treatment, your prescriber may recommend a very gradual taper over 12-16 weeks rather than abrupt cessation. This approach may help mitigate rebound hunger and allows time to adjust to managing appetite without pharmacological support. However, research specifically on tirzepatide tapering protocols remains limited [2].

Restarting Treatment After Discontinuation

If weight regain occurs after stopping Mounjaro, treatment can be restarted. You'll typically need to repeat the dose escalation protocol starting from 2.5mg, as previous tolerance doesn't guarantee immediate tolerability at higher doses after a treatment gap. Your UK prescriber will guide you through safe reinitiation.

Accessing Mounjaro Maintenance Prescriptions at Cured Pharmacy

At Cured Pharmacy, we provide ongoing prescription support for patients in the maintenance phase of their Mounjaro journey. Our UK-registered prescribers understand that maintenance dosing requires individualised assessment and regular clinical review to ensure continued safety and efficacy.

Mounjaro is available from £135.00 through our online consultation service, which takes under 3 minutes to complete. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all prescriptions to ensure they meet MHRA standards and GPhC guidelines. All medication is dispensed from our UK-registered pharmacy (GPhC 9012511) with discreet packaging and reliable delivery.

Your prescription will be reviewed every 12 weeks as part of ongoing care. This ensures your maintenance dose remains appropriate and allows for dose adjustments if your weight or clinical circumstances change. We also offer flexible prescription management, so you can adjust delivery timing to match your injection schedule without running out of medication.

Scientific References

1. Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or adjusting your current treatment plan.